{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T23:36:02Z","timestamp":1791416162808,"version":"4.3.3"},"reference-count":49,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2017,1,14]],"date-time":"2017-01-14T00:00:00Z","timestamp":1484352000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"name":"Sanofi Pasteur SMD"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intl J Gynecology &amp; Obste"],"published-print":{"date-parts":[[2017,3]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p><jats:styled-content style=\"fixed-case\">HPV<\/jats:styled-content>\u2010related diseases affect anogenital and oropharyngeal regions, heavily affecting the psychosexual dimension of both male and female individuals. <jats:styled-content style=\"fixed-case\">HPV<\/jats:styled-content> vaccination programs based on a bivalent or quadrivalent vaccine have opened broad perspectives for primary prevention. A nonavalent <jats:styled-content style=\"fixed-case\">HPV<\/jats:styled-content> vaccine (9v<jats:styled-content style=\"fixed-case\">HPV<\/jats:styled-content>), covering nine genotypes (<jats:styled-content style=\"fixed-case\">HPV<\/jats:styled-content>6, <jats:styled-content style=\"fixed-case\">HPV<\/jats:styled-content>11, <jats:styled-content style=\"fixed-case\">HPV<\/jats:styled-content>16, <jats:styled-content style=\"fixed-case\">HPV<\/jats:styled-content>18, <jats:styled-content style=\"fixed-case\">HPV<\/jats:styled-content>31, <jats:styled-content style=\"fixed-case\">HPV<\/jats:styled-content>33, <jats:styled-content style=\"fixed-case\">HPV<\/jats:styled-content>45, <jats:styled-content style=\"fixed-case\">HPV<\/jats:styled-content>52, and <jats:styled-content style=\"fixed-case\">HPV<\/jats:styled-content>58), might provide further improvement in terms of direct protection. In the present report, efficacy and safety data from 9v<jats:styled-content style=\"fixed-case\">HPV<\/jats:styled-content> vaccine development programs are examined. Efficacy data come from a pivotal trial, which was conducted among women aged 16\u201326\u00a0years randomly assigned to receive either the 9v<jats:styled-content style=\"fixed-case\">HPV<\/jats:styled-content> or the quadrivalent <jats:styled-content style=\"fixed-case\">HPV<\/jats:styled-content> (4v<jats:styled-content style=\"fixed-case\">HPV<\/jats:styled-content>) vaccine. The 9v<jats:styled-content style=\"fixed-case\">HPV<\/jats:styled-content> vaccine was shown to have potential benefits as compared with 4v<jats:styled-content style=\"fixed-case\">HPV<\/jats:styled-content>, increasing the overall estimated rate of prevention to 90% for cervical cancer and up to 80% for precancerous cervical lesions. For all other <jats:styled-content style=\"fixed-case\">HPV<\/jats:styled-content>\u2010related pre\u2010invasive and invasive lesions, 9v<jats:styled-content style=\"fixed-case\">HPV<\/jats:styled-content> showed potentially greater disease reduction, depending on the anatomic region examined. Thus, the 9v<jats:styled-content style=\"fixed-case\">HPV<\/jats:styled-content> vaccine shows clinical potential for the prevention of <jats:styled-content style=\"fixed-case\">HPV<\/jats:styled-content>\u2010related diseases in both sexes. Future adoption of 9v<jats:styled-content style=\"fixed-case\">HPV<\/jats:styled-content> will depend on factors including market price, cost\u2010effectiveness data, use of a two\u2010dose schedule, and safety and efficacy monitoring in real\u2010life programs.<\/jats:p>","DOI":"10.1002\/ijgo.12075","type":"journal-article","created":{"date-parts":[[2017,1,14]],"date-time":"2017-01-14T07:16:55Z","timestamp":1484378215000},"page":"258-265","source":"Crossref","is-referenced-by-count":23,"title":["Overview of the benefits and potential issues of the nonavalent <scp>HPV<\/scp> vaccine"],"prefix":"10.1002","volume":"136","author":[{"given":"Luciano","family":"Mariani","sequence":"first","affiliation":[{"name":"Regina Elena National Cancer Institute HPV\u2010Unit Gynecologic Oncology  Rome Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario","family":"Preti","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology University of Torino  Turin Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Cristoforoni","sequence":"additional","affiliation":[{"name":"Villa Montallegro  Genoa Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlo M.","family":"Stigliano","sequence":"additional","affiliation":[{"name":"Unit\u00e0 Ospedaliera Complessa Ginecologia Preventiva Azienda Sanitaria Provinciale di Cosenza  Castrovillari Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Perino","sequence":"additional","affiliation":[{"name":"Obstetrics and Gynecology Ospedali Riuniti Villa Sofia Cervello University of Palermo  Palermo Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2017,1,14]]},"reference":[{"key":"e_1_2_10_2_1","unstructured":"Global Cancer Observatory.http:\/\/gco.iarc.fr\/today\/fact-sheets-cancers?cancer=16&type=0&sex=2. Accessed October 26 2016."},{"key":"e_1_2_10_3_1","first-page":"465","article-title":"Human papillomaviruses","volume":"90","author":"International Agency for Research on Cancer","year":"2007","journal-title":"IARC Monogr Eval Carcinog Risks Hum"},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa021641"},{"key":"e_1_2_10_5_1","unstructured":"ICO Information Centre on HPV and Cancer.Human papillomavirus and related diseases report.http:\/\/www.hpvcentre.net\/statistics\/reports\/XWX.pdf. Published November 26 2016. Accessed November 30 2016."},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0909537"},{"key":"e_1_2_10_7_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1010971"},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.1086\/597307"},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(11)70287-X"},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2015-009915"},{"key":"e_1_2_10_11_1","first-page":"300","article-title":"Use of 9\u2010valent human papillomavirus (HPV) vaccine: Updated HPV vaccination recommendations of the advisory committee on immunization practices","volume":"64","author":"Petrosky E","year":"2015","journal-title":"MMWR Morb Mortal Wkly Rep."},{"key":"e_1_2_10_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(07)70158-5"},{"key":"e_1_2_10_13_1","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2334-10-214"},{"key":"e_1_2_10_14_1","doi-asserted-by":"publisher","DOI":"10.1158\/1055-9965.EPI-10-0131"},{"key":"e_1_2_10_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2008.12.028"},{"key":"e_1_2_10_16_1","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2407-10-259"},{"key":"e_1_2_10_17_1","doi-asserted-by":"publisher","DOI":"10.1158\/1055-9965.EPI-08-0151"},{"key":"e_1_2_10_18_1","doi-asserted-by":"publisher","DOI":"10.1097\/CCO.0b013e32832f511a"},{"key":"e_1_2_10_19_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2012.101"},{"key":"e_1_2_10_20_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.36.4596"},{"key":"e_1_2_10_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pvr.2015.06.003"},{"key":"e_1_2_10_22_1","first-page":"577","article-title":"Una rete di sorveglianza innovativa basata su ginecologi territoriali per studiare in Italia l'incidenza e la prevalenza dei condilomi genitali in donne: l'esperienza maturata","volume":"65","author":"Suligoi B","year":"2013","journal-title":"Minerva Ginecol"},{"key":"e_1_2_10_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.fertnstert.2006.01.051"},{"key":"e_1_2_10_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.fertnstert.2010.11.047"},{"key":"e_1_2_10_25_1","first-page":"4153","article-title":"Analysis of persistence of human papillomavirus infection in men evaluated by sampling multiple genital sites","volume":"19","author":"Capra G","year":"2015","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"e_1_2_10_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0015-0282(97)81454-9"},{"key":"e_1_2_10_27_1","doi-asserted-by":"publisher","DOI":"10.1155\/2014\/956901"},{"key":"e_1_2_10_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.fertnstert.2013.06.042"},{"key":"e_1_2_10_29_1","doi-asserted-by":"publisher","DOI":"10.1177\/2051013614557476"},{"key":"e_1_2_10_30_1","unstructured":"GiambiC.The progress of the HPV vaccination campaign: Vaccination coverage data to 31\/12\/2014[in Italian].http:\/\/www.epicentro.iss.it\/problemi\/hpv\/pdf\/Aggiornamento_HPV_31122014.pdf. Accessed October 26 2016."},{"key":"e_1_2_10_31_1","unstructured":"Italian Ministry of Health.National Prevention Plan 2014\u201318[in Italian].http:\/\/www.salute.gov.it\/imgs\/C_17_pubblicazioni_2285_allegato.pdf. Accessed November 26 2016."},{"key":"e_1_2_10_32_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-015-0178-4"},{"key":"e_1_2_10_33_1","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2015-1968"},{"key":"e_1_2_10_34_1","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2014.198"},{"key":"e_1_2_10_35_1","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djt460"},{"key":"e_1_2_10_36_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10552-015-0568-6"},{"key":"e_1_2_10_37_1","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2014.479"},{"key":"e_1_2_10_38_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(09)61248-4"},{"key":"e_1_2_10_39_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa061741"},{"key":"e_1_2_10_40_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(14)70841-2"},{"key":"e_1_2_10_41_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2015.07.015"},{"key":"e_1_2_10_42_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1405044"},{"key":"e_1_2_10_43_1","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2014-3745"},{"key":"e_1_2_10_44_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2015.06.088"},{"key":"e_1_2_10_45_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2015.08.059"},{"key":"e_1_2_10_46_1","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2407-12-30"},{"key":"e_1_2_10_47_1","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djv086"},{"key":"e_1_2_10_48_1","doi-asserted-by":"publisher","DOI":"10.1186\/1750-9378-7-38"},{"key":"e_1_2_10_49_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0068329"},{"key":"e_1_2_10_50_1","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djv282"}],"container-title":["International Journal of Gynecology &amp; Obstetrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fijgo.12075","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/obgyn.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ijgo.12075","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,17]],"date-time":"2023-08-17T21:31:58Z","timestamp":1692307918000},"score":1,"resource":{"primary":{"URL":"https:\/\/obgyn.onlinelibrary.wiley.com\/doi\/10.1002\/ijgo.12075"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,1,14]]},"references-count":49,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2017,3]]}},"alternative-id":["10.1002\/ijgo.12075"],"URL":"https:\/\/doi.org\/10.1002\/ijgo.12075","archive":["Portico"],"relation":{},"ISSN":["0020-7292","1879-3479"],"issn-type":[{"value":"0020-7292","type":"print"},{"value":"1879-3479","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,1,14]]}}}